These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas. Martin AG J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367 [TBL] [Abstract][Full Text] [Related]
4. Tazarotene 0.1% Cream as Monotherapy for Early-Stage Cutaneous T-Cell Lymphoma. Besner Morin C; Roberge D; Turchin I; Petrogiannis-Haliotis T; Popradi G; Pehr K J Cutan Med Surg; 2016 May; 20(3):244-8. PubMed ID: 26742957 [TBL] [Abstract][Full Text] [Related]
5. Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma. Kume M; Kiyohara E; Matsumura Y; Koguchi-Yoshioka H; Tanemura A; Hanaoka Y; Taminato M; Tashima H; Tomita K; Kubo T; Watanabe R; Fujimoto M Front Immunol; 2021; 12():651048. PubMed ID: 33859643 [TBL] [Abstract][Full Text] [Related]
6. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. Dummer R; Krasovec M; Röger J; Sindermann H; Burg G J Am Acad Dermatol; 1993 Dec; 29(6):963-70. PubMed ID: 8245262 [TBL] [Abstract][Full Text] [Related]
7. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Ferenczi K; Yawalkar N; Jones D; Kupper TS Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma. Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402 [TBL] [Abstract][Full Text] [Related]
9. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. Heald P; Mehlmauer M; Martin AG; Crowley CA; Yocum RC; Reich SD; J Am Acad Dermatol; 2003 Nov; 49(5):801-15. PubMed ID: 14576658 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Edelson RL Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. Tacastacas JD; Chan DV; Carlson S; Gerson SL; Dowlati A; Fu P; Lu K; Groft S; Rosenjack J; Honda K; McCormick TS; Cooper KD JAMA Dermatol; 2017 May; 153(5):413-420. PubMed ID: 28199478 [TBL] [Abstract][Full Text] [Related]
12. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174 [TBL] [Abstract][Full Text] [Related]
13. Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil. Kannangara AP; Levitan D; Fleischer AB J Drugs Dermatol; 2010 Aug; 9(8):1017-8. PubMed ID: 20684155 [TBL] [Abstract][Full Text] [Related]
14. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Ramelyte E; Dummer R; Guenova E Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295 [No Abstract] [Full Text] [Related]
15. Management of refractory early-stage cutaneous T-cell lymphoma. Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503 [TBL] [Abstract][Full Text] [Related]